Cargando…

Boswellia resin extract and propolis derived polyphenols in patients with type III chronic prostatitis/chronic pelvic pain syndrome: An Italian prospective multicenter study

OBJECTIVE: To assess the efficacy and safety of a treatment regimen based on rectal administration of Boswellia resin extract and propolis derived polyphenols in patients with type IIIa and type IIIb chronic prostatitis and chronic pelvic pain syndrome (CP/CPPS). METHODS: Patients with type IIIa and...

Descripción completa

Detalles Bibliográficos
Autores principales: Presicce, Fabrizio, Barrese, Francesco, Cantiani, Andrea, Filianoti, Alessio, Tuzzolo, Domenico, Di Palma, Paolo, Lauretti, Stefano, Brunori, Stefano, Martini, Marco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Second Military Medical University 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9051345/
https://www.ncbi.nlm.nih.gov/pubmed/35509480
http://dx.doi.org/10.1016/j.ajur.2021.09.002
_version_ 1784696533369749504
author Presicce, Fabrizio
Barrese, Francesco
Cantiani, Andrea
Filianoti, Alessio
Tuzzolo, Domenico
Di Palma, Paolo
Lauretti, Stefano
Brunori, Stefano
Martini, Marco
author_facet Presicce, Fabrizio
Barrese, Francesco
Cantiani, Andrea
Filianoti, Alessio
Tuzzolo, Domenico
Di Palma, Paolo
Lauretti, Stefano
Brunori, Stefano
Martini, Marco
author_sort Presicce, Fabrizio
collection PubMed
description OBJECTIVE: To assess the efficacy and safety of a treatment regimen based on rectal administration of Boswellia resin extract and propolis derived polyphenols in patients with type IIIa and type IIIb chronic prostatitis and chronic pelvic pain syndrome (CP/CPPS). METHODS: Patients with type IIIa and type IIIb CP/CPPS received one rectal suppository a day for 15 days per month for 3 consecutive months. Participants were evaluated with National Institutes of Health-Chronic Prostatitis Symptom Index (NIH-CPSI), the International Prostate Symptom Scores (IPSS), International Index of Erectile Function (IIEF), four-glass test, uroflowmetry, and prostate-specific antigen assessments at baseline and at Week 4, and Week 12. Primary endpoints were improvement in pain domain of NIH-CPSI and improvement of NIH-CPSI total score. Secondary outcomes included improvement of micturition and quality of life (QoL) domains of NIH-CPSI questionnaire. RESULTS: A total of 61 males were enrolled. No adverse events were reported. Significant improvements from baseline to Day 30 were reported for NIH-CPSI total score (mean difference: −9.2; p<0.01), NIH-CPSI pain domain (mean difference: −5.5; p<0.01), NIH-CPSI micturition domain, NIH-CPSI QoL domain, and IPSS total score (mean difference: −5.6; p<0.01). No significant changes from baseline in terms of IIEF score or maximum flow rate were observed. At final follow-up (Day 90), further significant improvements in terms of NIH-CPSI total score (mean difference: −12.2; p<0.01), NIH-CPSI pain domain (mean difference: −6.6; p<0.01), NIH-CPSI micturition domain, NIH-CPSI QoL domain, and IPSS total score were reported. CONCLUSION: Rectal administration of Boswellia resin extract and propolis derived polyphenols is well tolerated and delivers a significant symptomatic improvement in most patients with type IIIa and type IIIb CP/CPPS.
format Online
Article
Text
id pubmed-9051345
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Second Military Medical University
record_format MEDLINE/PubMed
spelling pubmed-90513452022-05-03 Boswellia resin extract and propolis derived polyphenols in patients with type III chronic prostatitis/chronic pelvic pain syndrome: An Italian prospective multicenter study Presicce, Fabrizio Barrese, Francesco Cantiani, Andrea Filianoti, Alessio Tuzzolo, Domenico Di Palma, Paolo Lauretti, Stefano Brunori, Stefano Martini, Marco Asian J Urol Original Article OBJECTIVE: To assess the efficacy and safety of a treatment regimen based on rectal administration of Boswellia resin extract and propolis derived polyphenols in patients with type IIIa and type IIIb chronic prostatitis and chronic pelvic pain syndrome (CP/CPPS). METHODS: Patients with type IIIa and type IIIb CP/CPPS received one rectal suppository a day for 15 days per month for 3 consecutive months. Participants were evaluated with National Institutes of Health-Chronic Prostatitis Symptom Index (NIH-CPSI), the International Prostate Symptom Scores (IPSS), International Index of Erectile Function (IIEF), four-glass test, uroflowmetry, and prostate-specific antigen assessments at baseline and at Week 4, and Week 12. Primary endpoints were improvement in pain domain of NIH-CPSI and improvement of NIH-CPSI total score. Secondary outcomes included improvement of micturition and quality of life (QoL) domains of NIH-CPSI questionnaire. RESULTS: A total of 61 males were enrolled. No adverse events were reported. Significant improvements from baseline to Day 30 were reported for NIH-CPSI total score (mean difference: −9.2; p<0.01), NIH-CPSI pain domain (mean difference: −5.5; p<0.01), NIH-CPSI micturition domain, NIH-CPSI QoL domain, and IPSS total score (mean difference: −5.6; p<0.01). No significant changes from baseline in terms of IIEF score or maximum flow rate were observed. At final follow-up (Day 90), further significant improvements in terms of NIH-CPSI total score (mean difference: −12.2; p<0.01), NIH-CPSI pain domain (mean difference: −6.6; p<0.01), NIH-CPSI micturition domain, NIH-CPSI QoL domain, and IPSS total score were reported. CONCLUSION: Rectal administration of Boswellia resin extract and propolis derived polyphenols is well tolerated and delivers a significant symptomatic improvement in most patients with type IIIa and type IIIb CP/CPPS. Second Military Medical University 2022-04 2021-09-11 /pmc/articles/PMC9051345/ /pubmed/35509480 http://dx.doi.org/10.1016/j.ajur.2021.09.002 Text en © 2022 Editorial Office of Asian Journal of Urology. Production and hosting by Elsevier B.V. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Original Article
Presicce, Fabrizio
Barrese, Francesco
Cantiani, Andrea
Filianoti, Alessio
Tuzzolo, Domenico
Di Palma, Paolo
Lauretti, Stefano
Brunori, Stefano
Martini, Marco
Boswellia resin extract and propolis derived polyphenols in patients with type III chronic prostatitis/chronic pelvic pain syndrome: An Italian prospective multicenter study
title Boswellia resin extract and propolis derived polyphenols in patients with type III chronic prostatitis/chronic pelvic pain syndrome: An Italian prospective multicenter study
title_full Boswellia resin extract and propolis derived polyphenols in patients with type III chronic prostatitis/chronic pelvic pain syndrome: An Italian prospective multicenter study
title_fullStr Boswellia resin extract and propolis derived polyphenols in patients with type III chronic prostatitis/chronic pelvic pain syndrome: An Italian prospective multicenter study
title_full_unstemmed Boswellia resin extract and propolis derived polyphenols in patients with type III chronic prostatitis/chronic pelvic pain syndrome: An Italian prospective multicenter study
title_short Boswellia resin extract and propolis derived polyphenols in patients with type III chronic prostatitis/chronic pelvic pain syndrome: An Italian prospective multicenter study
title_sort boswellia resin extract and propolis derived polyphenols in patients with type iii chronic prostatitis/chronic pelvic pain syndrome: an italian prospective multicenter study
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9051345/
https://www.ncbi.nlm.nih.gov/pubmed/35509480
http://dx.doi.org/10.1016/j.ajur.2021.09.002
work_keys_str_mv AT presiccefabrizio boswelliaresinextractandpropolisderivedpolyphenolsinpatientswithtypeiiichronicprostatitischronicpelvicpainsyndromeanitalianprospectivemulticenterstudy
AT barresefrancesco boswelliaresinextractandpropolisderivedpolyphenolsinpatientswithtypeiiichronicprostatitischronicpelvicpainsyndromeanitalianprospectivemulticenterstudy
AT cantianiandrea boswelliaresinextractandpropolisderivedpolyphenolsinpatientswithtypeiiichronicprostatitischronicpelvicpainsyndromeanitalianprospectivemulticenterstudy
AT filianotialessio boswelliaresinextractandpropolisderivedpolyphenolsinpatientswithtypeiiichronicprostatitischronicpelvicpainsyndromeanitalianprospectivemulticenterstudy
AT tuzzolodomenico boswelliaresinextractandpropolisderivedpolyphenolsinpatientswithtypeiiichronicprostatitischronicpelvicpainsyndromeanitalianprospectivemulticenterstudy
AT dipalmapaolo boswelliaresinextractandpropolisderivedpolyphenolsinpatientswithtypeiiichronicprostatitischronicpelvicpainsyndromeanitalianprospectivemulticenterstudy
AT laurettistefano boswelliaresinextractandpropolisderivedpolyphenolsinpatientswithtypeiiichronicprostatitischronicpelvicpainsyndromeanitalianprospectivemulticenterstudy
AT brunoristefano boswelliaresinextractandpropolisderivedpolyphenolsinpatientswithtypeiiichronicprostatitischronicpelvicpainsyndromeanitalianprospectivemulticenterstudy
AT martinimarco boswelliaresinextractandpropolisderivedpolyphenolsinpatientswithtypeiiichronicprostatitischronicpelvicpainsyndromeanitalianprospectivemulticenterstudy